<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We retrospectively assessed morphologic and cytogenetic responses to <z:chebi fb="0" ids="2038">5-azacytidine</z:chebi> and <z:chebi fb="0" ids="50131">decitabine</z:chebi> in a cohort of 42 adult therapy-related <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (tMDS) patients treated at Memorial Sloan-Kettering <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Center and in 2 industry-sponsored <z:chebi fb="0" ids="50131">decitabine</z:chebi> trials (D0007 and DACO-020) </plain></SENT>
<SENT sid="1" pm="."><plain>The overall response rate (complete remission+marrow CR+hematologic improvement) was 38%, including 6 patients with complete remission (14%), 6 with marrow CR with or without hematologic improvement (14%), and 4 with hematologic improvement alone (10%) </plain></SENT>
<SENT sid="2" pm="."><plain>We conclude that DNA methyltransferase inhibitors showed activity in tMDS that is roughly comparable to that seen in de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>